Insulin-like growth factor binding protein-3 serves as a biomarker for resistance to enzalutamide in prostate cancer - PubMed
6 hours ago
- #IGFBP3
- #prostate cancer
- #enzalutamide resistance
- Insulin-like growth factor binding protein-3 (IGFBP3) serves as a biomarker for enzalutamide resistance (EnzR) in prostate cancer.
- Enzalutamide resistance is a major challenge in treating castration-resistant prostate cancer, often leading to tumor progression.
- Study analyzed 1273 transcriptomics datasets to identify key genes involved in EnzR and developed EnzR scores to predict tumor progression.
- IGFBP3 promotes proliferation of drug-resistant cells and enhances ENZ resistance via epithelial-mesenchymal transition (EMT) signaling.
- The study established a new EnzR scoring model that can predict clinical prognosis post-surgery in prostate cancer patients.
- IGFBP3 is identified as a potential therapeutic target for overcoming ENZ resistance in prostate cancer.